m6A RNA Methylation (Epitranscriptomics) in Neurodegeneration

m6A RNA Methylation (Epitranscriptomics) in Neurodegeneration

Introduction

N6-methyladenosine (m6A) is the most prevalent internal modification in eukaryotic mRNA, playing crucial roles in RNA splicing, stability, translation, and localization. In the context of neurodegenerative diseases, m6A dysregulation affects [APP](/entities/app) processing, tau phosphorylation, [alpha-synuclein](/proteins/alpha-synuclein) expression, and neuroinflammation. This pathway page examines the m6A machinery—writers, erasers, and readers—and their contribution to Alzheimer's disease, Parkinson's disease, and ALS pathogenesis.

m6A Epitranscriptomics Machinery

Writers (m6A Methyltransferases)

The m6A writer complex catalyzes the installation of methyl groups on adenosine residues in mRNA. The core complex consists of:

| Component | Function | Brain Expression |
|-----------|----------|------------------|
| METTL3 | Catalytic subunit, SAM-binding domain | High in neurons |
| METTL14 | Scaffold subunit, recognition element | High in neurons |
| WTAP | Regulatory subunit, nuclear localization | Moderate |
| VIRMA (KIAA1429) | Regulatory, 3' UTR bias | Moderate |
| RBM15/15B | Target RNA recruitment | Low |

Erasers (m6A Demethylases)

FTO and ALKBH5 remove m6A modifications, providing dynamic regulation:

| Enzyme | Mechanism | Disease Relevance |
|--------|-----------|-------------------|
| FTO | 2-oxoglutarate-dependent dioxygenase | AD risk gene, obesity |
| ALKBH5 | Fe(II)/2-OG dioxygenase | Spermatogenesis, potential in PD |

Readers (m6A-Binding Proteins)

m6A RNA Methylation (Epitranscriptomics) in Neurodegeneration

Introduction

N6-methyladenosine (m6A) is the most prevalent internal modification in eukaryotic mRNA, playing crucial roles in RNA splicing, stability, translation, and localization. In the context of neurodegenerative diseases, m6A dysregulation affects [APP](/entities/app) processing, tau phosphorylation, [alpha-synuclein](/proteins/alpha-synuclein) expression, and neuroinflammation. This pathway page examines the m6A machinery—writers, erasers, and readers—and their contribution to Alzheimer's disease, Parkinson's disease, and ALS pathogenesis.

m6A Epitranscriptomics Machinery

Writers (m6A Methyltransferases)

The m6A writer complex catalyzes the installation of methyl groups on adenosine residues in mRNA. The core complex consists of:

| Component | Function | Brain Expression |
|-----------|----------|------------------|
| METTL3 | Catalytic subunit, SAM-binding domain | High in neurons |
| METTL14 | Scaffold subunit, recognition element | High in neurons |
| WTAP | Regulatory subunit, nuclear localization | Moderate |
| VIRMA (KIAA1429) | Regulatory, 3' UTR bias | Moderate |
| RBM15/15B | Target RNA recruitment | Low |

Erasers (m6A Demethylases)

FTO and ALKBH5 remove m6A modifications, providing dynamic regulation:

| Enzyme | Mechanism | Disease Relevance |
|--------|-----------|-------------------|
| FTO | 2-oxoglutarate-dependent dioxygenase | AD risk gene, obesity |
| ALKBH5 | Fe(II)/2-OG dioxygenase | Spermatogenesis, potential in PD |

Readers (m6A-Binding Proteins)

Readers interpret the m6A code and execute downstream functions:

| Reader | Function | Neuronal Role |
|--------|----------|---------------|
| YTHDF1 | Translation initiation | Synaptic plasticity |
| YTHDF2 | mRNA decay | Transcriptional regulation |
| YTHDF3 | Co-translation | mRNA fate decision |
| YTHDC1 | Splicing regulation | Neuronal development |
| YTHDC2 | Translation enhancement | Spermatogenesis |

Molecular Mechanisms in Neurodegeneration

Alzheimer's Disease

m6A dysregulation contributes to AD pathogenesis through multiple mechanisms:

Parkinson's Disease

Amyotrophic Lateral Sclerosis / Frontotemporal Dementia

Therapeutic Implications

Targeting the m6A Machinery

| Target | Approach | Status | Disease |
|--------|----------|--------|---------|
| METTL3 inhibitors | Small molecule | Preclinical | AD, PD |
| FTO inhibitors | Compound screening | Preclinical | PD |
| YTHDF1 agonists | Peptide mimetics | Discovery | AD |
| ALKBH5 modulators | Structure-based design | Early | PD |

Clinical Considerations

Summary

The epitranscriptomics landscape—particularly m6A RNA methylation—represents a novel frontier in understanding neurodegeneration. The dynamic interplay between writers, erasers, and readers governs RNA metabolism critical to neuronal health. Dysregulation of this system contributes to protein aggregation, synaptic dysfunction, and neuroinflammation across AD, PD, and ALS. Therapeutic modulation of m6A machinery offers promising but challenging opportunities for disease modification.

See Also

• [RNA Metabolism in Neurodegeneration](/mechanisms/rna-metabolism-dysregulation)
• [Epigenetic Regulation in AD](/mechanisms/epigenetic-regulation-alzheimers)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
• [Autophagy](/mechanisms/autophagy)

Confidence Assessment

| Dimension | Score |
|-----------|-------|
| Supporting Studies | Low (references need verification) |
| Replication | Not established |
| Effect Sizes | Variable |
| Contradicting Evidence | Not documented |
| Mechanistic Completeness | Partial |

Overall Confidence: Low - requires verification of cited literature

Note: This page contains previously cited references that were found to be hallucinated. The content is retained but all references have been removed pending verification with valid sources.